Safety and efficacy of the rSh28GST urinary schistosomiasis vaccine: A phase 3 randomized, controlled trial in Senegalese children.

• Váldodahkkit: Gilles Riveau (Dahkki), Anne-Marie Schacht (Dahkki), Jean-Pierre Dompnier (Dahkki), Dominique Deplanque (Dahkki), Modou Seck (Dahkki), Nawal Waucquier (Dahkki), Simon Senghor (Dahkki), Delphine Delcroix-Genete (Dahkki), Emmanuel Hermann (Dahkki), Noureddine Idris-Khodja (Dahkki), Claire Levy-Marchal (Dahkki), Monique Capron (Dahkki), André Capron (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Public Library of Science (PLoS), 2018-12-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

<h4>Background</h4>Urinary schistosomiasis, the result of infection by Schistosoma haematobium (Sh), remains a major global health concern. A schistosome vaccine could represent a breakthrough in schistosomiasis control strategies, which are presently based on treatment with praziquantel...